Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment

ACP Journal Club17 May 2011Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatmentJames Douketis, MDJames Douketis, MDSt. Joseph’s Hospital, Hamilton, Ontario, Canada (J.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-10-201105170-02006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationThe EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510. https://pubmed.ncbi.nlm.nih.gov/21128814Clinical Impact RatingsHematology: References1 Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PMID: 8707165] Google Scholar2 Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22. [PMID: 19071881] Google Scholar3 Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:454S-545S. [PMID: 18574272] Google Scholar4 Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604. [PMID: 19657123] Google Scholar5 Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16:3436-41. [PMID: 20858185] Google Scholar Author, Article, and Disclosure InformationAuthors: James Douketis, MDAffiliations: St. Joseph’s Hospital, Hamilton, Ontario, Canada (J.D.)This article was published at Annals.org on 3 May 2011. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoApixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacement James Douketis Metrics 17 May 2011Volume 154, Issue 10 Page: JC5-6 Keywords Anticoagulants Apixaban Deep vein thrombosis Drugs Hemorrhage Low molecular weight heparin Safety Surgery Venous thromboembolism Vitamin K ePublished: 17 May 2011 Issue Published: 17 May 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...